GSK Plc halted development of an experimental drug for chronic cough, saying it was unlikely to transform patient care.

The British drugmaker said it would no longer continue testing camlipixant for refractory chronic cough, sending its shares down as much as 4.5% on Friday.

葛兰素史克公司（GSK Plc）宣布停止开发一款针对慢性咳嗽的实验性药物，并表示该药物 " 不太可能改变患者的治疗现状 "。

这家英国制药公司宣布将终止针对难治性慢性咳嗽的 camlipixant 药物试验，导致其股价在周五下跌达 4.5%。